Cowa LLC Purchases 1,500 Shares of Pfizer Inc. (NYSE:PFE)

Cowa LLC lifted its position in Pfizer Inc. (NYSE:PFE) by 21.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 8,528 shares of the biopharmaceutical company’s stock after purchasing an additional 1,500 shares during the period. Cowa LLC’s holdings in Pfizer were worth $226,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in PFE. Swedbank AB grew its holdings in shares of Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after purchasing an additional 37,636 shares during the last quarter. McAdam LLC grew its holdings in shares of Pfizer by 13.9% in the third quarter. McAdam LLC now owns 21,533 shares of the biopharmaceutical company’s stock worth $623,000 after purchasing an additional 2,628 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of Pfizer in the third quarter worth approximately $146,481,000. apricus wealth LLC grew its holdings in shares of Pfizer by 4.2% in the third quarter. apricus wealth LLC now owns 104,970 shares of the biopharmaceutical company’s stock worth $3,038,000 after purchasing an additional 4,200 shares during the last quarter. Finally, Rowlandmiller & PARTNERS.ADV grew its holdings in shares of Pfizer by 1.1% in the third quarter. Rowlandmiller & PARTNERS.ADV now owns 84,109 shares of the biopharmaceutical company’s stock worth $2,434,000 after purchasing an additional 902 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.32 on Friday. The business has a fifty day simple moving average of $26.30 and a two-hundred day simple moving average of $27.42. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $149.14 billion, a P/E ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.10 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. Pfizer’s payout ratio is presently 121.99%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on PFE shares. Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Wolfe Research started coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.